Current and Emerging Treatment Options for Lung Cancer and Head & Neck Cancer

Released On
July 22, 2020

Expires On
July 30, 2021

Media Type

Completion Time
150 minutes

Emergency Medicine, Hematology-Oncology, Otolaryngology, Pathology, Pharmacy, Primary Care, Pulmonology, Surgery


Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Amedco LLC and CancerNet.

Supported by an independent educational grant from Merck Sharp & Dohme, Bristol-Myers Squibb..

Credit Available

  • Physicians — maximum of 2.5 AMA PRA Category 1 Credit(s)
  • Nurses — 2.5 Nursing Contact Hours

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the educational needs of medical oncologists, radiation oncologists, nurse practitioners, physician assistants, nurses on the latest advances in the diagnosis, and treatment of non-small-cell lung cancer (NSCLC), small cell lung cancer (SCLC), and head & neck carcinoma.

Program Overview

This activity will cover topic on the diagnosis, treatment and management of patients with non-small-cell lung cancer (NSCLC), small cell lung cancer (SCLC), and head & neck carcinoma.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Outline the optimal use of anti-PD-1, PD-L1 antibodies and combination approaches in the treatment of non-small cell lung cancer
  • Appraise the role of predictive biomarkers in clinical decision‐making for immune checkpoint inhibitor therapies in lung cancer
  • Assess the clinical implication of PD-1/PD-L1 and CTLA-4 inhibitors and combination therapies in patients with small cell lung cancer
  • Outline the clinical implication of PD-1 and PD-L1 blockade in squamous cell carcinoma of head and neck


Mark A. Socinski, MD

Mark A. Socinski, MD

Medical Oncologist and Executive Medical Director, Florida Hospital Cancer Institute and AdventHealth Cancer Institute
Orlando, FL

Lauren A. Byers, MD

Lauren A. Byers, MD, MS

Associate Professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center
Houston, TX

David Gerber, MD

David Gerber, MD

Professor of Internal Medicine within the Hematology/Oncology Division, The University of Texas Southwestern Medical Center
Dallas, TX

Ezra Cohen, MD


Chief, Division of Hematology-Oncology, Professor of Medicine, Moores Cancer Center
San Diego, CA

Accreditation Statement


In support of improving patient care, this activity has been planned and implemented by Amedco LLC and CancerNet LLC. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Credit Designation

Credit Designation Statement – Amedco LLC designates this enduring activity for a maximum of 2.50 AMA PRA Category 1 Credits™ for physicians and 2.50 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved (C7 SCS 6.1-­‐6.2, 6.5). All individuals in a position to control the content of CE are listed below.

Mark Socinski, MD

  • Consulting/advisory committee: AstraZeneca, Bayer, Bristol-Myers Squibb, Genentech, Guardant, Merck
  • Speaker’s Bureau: AstraZeneca, Bayer, Bristol-Myers Squibb, Genentech, Guardant, Merck
  • Research Funding: AstraZeneca, Genentech, Novartis, Spectrum

Lauren Averett Byers, MD, MS

  • Consulting/advisory committee: AstraZeneca, AbbVie, GenMab, PharmaMar, Sierra Oncology, Bristol-Myers Squibb, Alethia Biotherapeutics, Merck, Jazz Pharmaceuticals
  • Research Funding: AbbVie, AstraZeneca, Tolero Pharmaceuticals, GenMab, Sierra Oncology

David Gerber, MD

  • Consulting/advisory committee: BMS, Karyopharm, Samsung Bioepis
  • Research funding: AstraZeneca, BerGenBio, Karyopharm
  • Stock ownership: Gilead


  • Consulting/advisory committee: ALX Oncology, Ascendis, Bayer, Bioline Rx, BMS, Debio, Dynavax, MSD, Merck, Regeneron, Sanofi

Planners and Managers Disclosures

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME webcast:

  • Mark A. Socinski, MD
    • Consulting/advisory committee: AstraZeneca, Bayer, Bristol-Myers Squibb, Genentech, Guardant, Merck
    • Speaker’s Bureau: AstraZeneca, Bayer, Bristol-Myers Squibb, Genentech, Guardant, Merck
    • Research Funding: AstraZeneca, Genentech, Novartis, Spectrum
  • Kamatham A. Naidu, PhD (CancerNet, LLC), has no relevant financial relationships.
  • Brian Waggoner (CancerNet, LLC) has no relevant financial relationships to disclose.
  • Sheryl Morgan (Amedco) has no relevant financial relationships to disclose.

Instructions for Participation and Credit

There are no fees for participating and receiving CME/CE credit for this enduring activity. To receive CME/CE credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Submit the evaluation form to the Med Learning Group.
  4. Certificates will be emailed to participants.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

Amedco and CancerNet require that faculty participating in any CME/CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.


Amedco makes every effort to develop CME/CE activities that are scientifically based.

This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME/CE questions, please contact: Amedco at:

For questions regarding content, please contact: CancerNet at